The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Ludvig Svensson, Penser Access by Carnegie, Tel: +46 8 463 80 00. Penser Access by Carnegie

  Quarterly Report 2 23/24, March 27, 2024
The recent granting of Fast Track designation by the U.S. FDA for our flagship product Diamyd® is a milestone that not only accelerates the path to bringing our innovative treatment to patients with Type 1 Diabetes but also validates the urgent need for our therapy. This status enhances our ability to work closely with the FDA to expedite the review process, bringing us closer to making a tangible impact on the lives of those diagnosed with type...
The recent granting of Fast Track designation by the U.S. FDA for our flagship product Diamyd® is a milestone that both accelerates the path to bringing our innovative treatment to patients with Type 1 Diabetes and validates the urgent need for our therapy.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
June 3 − June 6, 2024
BIO International convention
June 21 − June 24, 2024
ADA 84th Scientific Sessions
June 26, 2024
Quarterly Report III
Quarterly Report 3 2023/2024
September 9 − September 13, 2024
EASD 2024
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of March 28, 2024

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 12 257 304 12.91 10.25
Lindkvist, Bertil 8 700 000 9.16 7.27
Nordnet Pension 4 902 383 5.16 4.10
Essen-Möller, Anders * 741 630 3 017 040 3.96 8.72
Essen-Möller, Maria-Teresa 400 000 963 998 1.44 4.15
Konstruktions o Försäljningsaktiebolag 906 250 0.95 0.76
Essen-Möller, Jon 400 000 287 015 0.72 3.58
Esssen-Möller, Martin 400 000 306 440 0.74 3.60
Hillborg, Erika 400 000 190 000 0.62 3.50
Essenshaw, My 400 000 181 002 0.61 3.50
Remaining shareholders 60 494 934 63.71 50.57
Total 2 741 630 92 206 366 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS